Long-term antiviral therapy for babies with CMV brain problems
Part of Infections clinical trials.
This study tests if giving antiviral medicine for 4 to 6 months helps babies born with cytomegalovirus (CMV) infection that affects their brain and development. It aims to see if longer treatment can prevent problems like hearing loss or delayed growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed CMV infection in urine, blood, or fluid within 3 weeks after birth
- Moderate or severe symptoms from CMV affecting the brain or multiple body systems
- Baby must be enrolled by 30 days old
- Parent or guardian must give written permission
- Baby must be born at 32 weeks or later
- Baby must weigh at least 1.8 kg (about 4 pounds) at birth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow children born in New York State who were tested for cytomegalovirus (CMV) as newborns. It aims to understand their long-term health and development, whether they were confirmed to have CMV, a false positive, or even a late detection if born early.
This Phase 2 trial tests an immune treatment made from donor T-cells to help the body fight congenital CMV infection in newborns. It may be an option if your baby is very young, has evidence of CMV infection, and meets specific blood, kidney, and liver safety limits.
This is an observational study that looks at how babies with congenital CMV infection are diagnosed and managed in real life. It may help doctors understand which care approaches are used and how they relate to outcomes over time.
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests valganciclovir to see if it can reduce CMV virus in the blood for people with advanced HIV and a low CD4 count. It aims to prevent CMV from causing serious disease.
Hear when a new Congenital CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.